iNtRON has developed an advanced bacteriophage engineering platform technology based on modified random mutagenesis

• Development of transposon technology following customized CRISPR/Cas system for bacteriophages
• 2^nd Technology for generating robotic bacteriophages

BOSTON AND SEOUL, SOUTH KOREA, Oct. 17, 2022 /PRNewswire/ — iNtRON biotechnology (“iNtRON”, www.intodeworld.com) announced today that^nd Generation techniques for robotic bacteriophage development. In addition to our previously published customized CRISPR/Cas system for improved bacteriophage engineering, the random transposon mutagenesis technique can now be applied to bacteriophage genomes. This advance identifies non-essential genes from the bacteriophage genome, greatly facilitating gene transfer and genome size control to confer additional functions at target sites.

iNtRON not only neutralizes viruses with PHAGERUS-based bacteriophages^® PHAGERIA also applies^® fageriaros^® Fundamental technology for immunotherapeutic drug development. To that end, it is necessary to secure more advanced robotic bacteriophage technology to design and produce bacteriophage genomes at will.

The developed technology follows the ‘REVERSE’ genetics technology, which is a customized CRISPR/Cas System for bacteriophages, followed by ‘FOWARD’ genetics, which facilitates finding and removing non-essential genes within bacteriophages. Technology. In other words, iNtRON reserves 2.^nd A generation-based technology that enables the development of robotic bacteriophages with desired characteristics by introducing necessary genes into the remaining empty space after removing non-essential genes.

Dr. Jee Soo, SON, Head of iNtRON’s BD Division, said, “This is the first case of utilizing random mutagenesis to test gene function in bacteriophages, and the method has been improved.” The optimized random mutagenesis technology developed this time is a transposon-based technology used in conventional bacteria, but iNtRON , adding techniques for selecting improved bacteriophages that have been mutagenized by experimental methods.”

In this regard, company officials believe that iNtRON will continue to upgrade and accelerate its technology to improve genes regardless of their size, and by selectively removing non-essential genes, improved bacteriophage types. and plans to gradually expand the category. Various native bacteriophages isolated by iNtRON.

YOON, Kyung Won, CEO of iNtRON, said:^® Antiviral drug development, PHAGERIA^® fageriaros^® Regarding the development of anticancer drugs and immunomodulators, we plan to expand the development fields and target areas in the future. ”

About iNtRON Biotechnology, Inc.

iNtRON is a leader in bacteriophage-based technology for the development and exploration of the “Immunology and Immunotherapy” market. Pursuing global research and business development (R&BD) investments since its inception, and after entering IPO on KOSDAQ, accelerating development, the company has developed various “first concept” biopharmaceuticals and conducted clinical studies By doing so, we have refined the innovation of new biopharmaceuticals. step by step. We are committed to developing ground-breaking innovations in infectious diseases and in the fields of “Immunology and Immunotherapy”.

About iNtODEWorld Co., Ltd.

iNtRON establishes 100% subsidiary iNtO in the USDE2017 World Co., Ltd.DEWORLD was originally registered in Delaware and is now headquartered in Boston.into theDEWORLD provides iNtRON news, updates and platform development progress to potential global partners and collaborators, as well as original US R&BD productions.

inquiry

Yoon Kyung-won (Kevin) / CEO, Vice President / kwyoon@intron.co.kr
SHIN, Tae Kyu (TK) / BD Team Leader / tkshin@intron.co.kr
BD Team / partner@intron.co.kr
www.intodeworld.com

iNtRON Biotechnology Co., Ltd.

148 708, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do

into theDEWorld Co., Ltd.

1500 District Avenue, Suite 2097, Burlington, MA 01803, USA

That’s the intron.

View original content: https://www.prnewswire.com/news-releases/intron-developed-advanced-bacteriophage-engineering-platform-technology-based-on-modified-random-mutagenesis-301651571.html

Source: iNtRON Biotechnology, Inc.

Company code: South Korea: 048530

.